Literature DB >> 25801152

A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.

Ken-ichi Kusakabe1, Nobuyuki Ide2, Yataro Daigo3, Takeshi Itoh2, Takahiko Yamamoto4, Eiichi Kojima2, Yasunori Mitsuoka2, Genta Tadano2, Sachie Tagashira2, Kenichi Higashino4, Yousuke Okano4, Yuji Sato2, Makiko Inoue2, Motofumi Iguchi2, Takayuki Kanazawa2, Yukichi Ishioka2, Keiji Dohi2, Yasuto Kido5, Shingo Sakamoto5, Shigeru Ando2, Masahiro Maeda4, Masayo Higaki4, Hidenori Yoshizawa2, Hitoshi Murai2, Yusuke Nakamura6.   

Abstract

Mps1, also known as TTK, is a dual-specificity kinase that regulates the spindle assembly check point. Increased expression levels of Mps1 are observed in cancer cells, and the expression levels correlate well with tumor grade. Such evidence points to selective inhibition of Mps1 as an attractive strategy for cancer therapeutics. Starting from an aminopyridine-based lead 3a that binds to a flipped-peptide conformation at the hinge region in Mps1, elaboration of the aminopyridine scaffold at the 2- and 6-positions led to the discovery of 19c that exhibited no significant inhibition for 287 kinases as well as improved cellular Mps1 and antiproliferative activities in A549 lung carcinoma cells (cellular Mps1 IC₅₀=5.3 nM, A549 IC₅₀=26 nM). A clear correlation between cellular Mps1 and antiproliferative IC₅₀ values indicated that the antiproliferative activity observed in A549 cells would be responsible for the cellular inhibition of Mps1. The X-ray structure of 19c in complex with Mps1 revealed that this compound retains the ability to bind to the peptide flip conformation. Finally, comparative analysis of the X-ray structures of 19c, a deamino analogue 33, and a known Mps1 inhibitor bound to Mps1 provided insights into the unique binding mode at the hinge region.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Flipped peptide; Inhibitor; Kinase; Monopolar spindle 1; Mps1; Peptide flip; TTK

Mesh:

Substances:

Year:  2015        PMID: 25801152     DOI: 10.1016/j.bmc.2015.02.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.

Authors:  Ana Rita R Maia; Simon Linder; Ji-Ying Song; Chantal Vaarting; Ute Boon; Colin E J Pritchard; Arno Velds; Ivo J Huijbers; Olaf van Tellingen; Jos Jonkers; René H Medema
Journal:  Br J Cancer       Date:  2018-05-08       Impact factor: 7.640

2.  Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722).

Authors:  Hannah L Woodward; Paolo Innocenti; Kwai-Ming J Cheung; Angela Hayes; Jennie Roberts; Alan T Henley; Amir Faisal; Grace Wing-Yan Mak; Gary Box; Isaac M Westwood; Nora Cronin; Michael Carter; Melanie Valenti; Alexis De Haven Brandon; Lisa O'Fee; Harry Saville; Jessica Schmitt; Rosemary Burke; Fabio Broccatelli; Rob L M van Montfort; Florence I Raynaud; Suzanne A Eccles; Spiros Linardopoulos; Julian Blagg; Swen Hoelder
Journal:  J Med Chem       Date:  2018-09-10       Impact factor: 7.446

3.  Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.

Authors:  Ruoyu Miao; Yan Wu; Haohai Zhang; Huandi Zhou; Xiaofeng Sun; Eva Csizmadia; Lian He; Yi Zhao; Chengyu Jiang; Rebecca A Miksad; Tahereh Ghaziani; Simon C Robson; Haitao Zhao
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

4.  TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.

Authors:  Gonghua Qi; Hanlin Ma; Yingwei Li; Jiali Peng; Jingying Chen; Beihua Kong
Journal:  Cell Death Dis       Date:  2021-12-07       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.